A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro... SDZ ASM 981, a novel ascomycin macrolactam derivative, has high anti‐inflammatory activity in animal models of allergic contact dermatitis and shows clinical efficacy in atopic dermatitis, allergic contact dermatitis and psoriasis, after topical application. Here we report on the in vitro activities of this promising new drug. SDZ ASM 981 inhibits the proliferation of human T cells after antigen‐specific or non‐specific stimulation. It downregulates the production of Th1 (interleukin (IL)‐2, interferon‐γ) and Th2 (IL‐4, IL‐10) type cytokines after antigen‐specific stimulation of a human T‐helper cell clone isolated from the skin of an atopic dermatitis patient. SDZ ASM 981 inhibits the phorbol myristate acetate/phytohaemagglutinin‐stimulated transcription of a reporter gene coupled to the human IL‐2 promoter in the human T‐cell line Jurkat and the IgE/antigen‐mediated transcription of a reporter gene coupled to the human tumour necrosis factor (TNF)‐α promoter in the murine mast‐cell line CPII. It does not, however, affect the human TNF‐α promoter controlled transcription of a reporter gene in a murine dendritic cell line (DC18 RGA) after stimulation via the FcγRIII receptor. SDZ ASM 981 also prevents the release of preformed pro‐inflammatory mediators from mast cells, as shown in the murine cell line CPII after stimulation with IgE/antigen. In summary, these results demonstrate that SDZ ASM 981 is a specific inhibitor of the production of pro‐inflammatory cytokines from T cells and mast cells in vitro. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Dermatology Wiley

A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

Loading next page...
 
/lp/wiley/a-novel-anti-inflammatory-drug-sdz-asm-981-for-the-treatment-of-skin-YVUnnI070g
Publisher
Wiley
Copyright
Copyright © 1999 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0007-0963
eISSN
1365-2133
DOI
10.1046/j.1365-2133.1999.02974.x
Publisher site
See Article on Publisher Site

Abstract

SDZ ASM 981, a novel ascomycin macrolactam derivative, has high anti‐inflammatory activity in animal models of allergic contact dermatitis and shows clinical efficacy in atopic dermatitis, allergic contact dermatitis and psoriasis, after topical application. Here we report on the in vitro activities of this promising new drug. SDZ ASM 981 inhibits the proliferation of human T cells after antigen‐specific or non‐specific stimulation. It downregulates the production of Th1 (interleukin (IL)‐2, interferon‐γ) and Th2 (IL‐4, IL‐10) type cytokines after antigen‐specific stimulation of a human T‐helper cell clone isolated from the skin of an atopic dermatitis patient. SDZ ASM 981 inhibits the phorbol myristate acetate/phytohaemagglutinin‐stimulated transcription of a reporter gene coupled to the human IL‐2 promoter in the human T‐cell line Jurkat and the IgE/antigen‐mediated transcription of a reporter gene coupled to the human tumour necrosis factor (TNF)‐α promoter in the murine mast‐cell line CPII. It does not, however, affect the human TNF‐α promoter controlled transcription of a reporter gene in a murine dendritic cell line (DC18 RGA) after stimulation via the FcγRIII receptor. SDZ ASM 981 also prevents the release of preformed pro‐inflammatory mediators from mast cells, as shown in the murine cell line CPII after stimulation with IgE/antigen. In summary, these results demonstrate that SDZ ASM 981 is a specific inhibitor of the production of pro‐inflammatory cytokines from T cells and mast cells in vitro.

Journal

British Journal of DermatologyWiley

Published: Aug 1, 1999

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off